Dr. Tam Discusses BTK Inhibition in CLL

Constantine S. Tam, MD
Published: Thursday, Feb 02, 2017



Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

In a dose-escalation study, the BTK inhibitor ibrutinib (Imbruvica) was explored in patients with CLL. Most of the current available agents aren’t selective enough and have not exploited the full potential of BTK inhibition in CLL, says Tam.

Remission rates has been observed at 34% in patients with Waldenström's macroglobulinemia when BTK inhibition has been pushed with higher rates of ibrutinib. By increasing the level of BTK inhibition, remission rates have more than doubled in patients.
 
SELECTED
LANGUAGE


Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

In a dose-escalation study, the BTK inhibitor ibrutinib (Imbruvica) was explored in patients with CLL. Most of the current available agents aren’t selective enough and have not exploited the full potential of BTK inhibition in CLL, says Tam.

Remission rates has been observed at 34% in patients with Waldenström's macroglobulinemia when BTK inhibition has been pushed with higher rates of ibrutinib. By increasing the level of BTK inhibition, remission rates have more than doubled in patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x